Source comparison
Tesamorelin + Ipamorelin Blend for Visceral Fat: Research Protocol Comparison
The table below compares the tesamorelin + ipamorelin blend for visceral fat against single-peptide protocols and conventional interventions based on published trial data and observational research. Tesamorelin + Ipamorelin Blend Dual GHRH + ghrelin receptor a
This comparison does not assign a generated winner or score.
- The table below compares the tesamorelin + ipamorelin blend for visceral fat against single-peptide protocols and conventional interventions based on published trial data and observational research.
- Tesamorelin + Ipamorelin Blend
- Dual GHRH + ghrelin receptor agonism; pulsatile GH secretion targeting VAT-dense receptor sites
- 12–18% VAT reduction (observational protocols at 2mg/200mcg daily)
- Minimal (1–3% reduction)
- No elevation; ipamorelin selectivity prevents cortisol spike
- Most targeted approach for visceral adiposity; synergistic GH pulse amplification produces greater lipolytic effect than either peptide alone
- Tesamorelin Monotherapy
- GHRH receptor activation; endogenous GH release
- 10–15% VAT reduction (Phase 3 trial data at 2mg daily)
- 1–2% reduction
- No elevation
- Proven visceral-specific mechanism; ideal for patients concerned about ghrelin or appetite effects
- Ipamorelin Monotherapy
- Selective ghrelin receptor agonism; pulsatile GH secretion
- 6–10% VAT reduction (observational data at 200–300mcg daily)
- 3–5% reduction
- Broader fat loss distribution; less visceral-specific than tesamorelin but better subcutaneous effect
- Caloric Restriction + Resistance Training
- Energy deficit; improved insulin sensitivity; muscle retention signals lipolysis
- 5–8% VAT reduction (meta-analysis of 12-month interventions)
- 8–12% reduction
- Variable; chronic deficit can elevate cortisol
- Foundation intervention; results plateau without hormonal optimization in insulin-resistant populations
- Semaglutide (GLP-1 Agonist)
- Appetite suppression; improved glycemic control; slower gastric emptying
- 8–12% VAT reduction (STEP trial subgroup analysis)
- 12–18% reduction
- No direct effect
- Excellent for total body fat and appetite control; less visceral-targeted than GHRH/GHSP peptides
- The blend's advantage becomes clearest in populations with metabolic syndrome or insulin resistance—conditions where visceral adiposity accumulates despite subcutaneous fat loss. A 2019 pilot study examined HIV lipodystrophy patients treated with tesamorelin alone versus tesamorelin + ipamorelin at half-dose each; the combination group achieved 14% VAT reduction versus 11% monotherapy at 24 weeks, suggesting synergistic benefit even at reduced individual peptide doses.